HCC Risk Biomarkers
AFP-L3 and DCP
Wako's HCC risk biomarkers AFP-L3 and DCP are intended for in vitro diagnostic use as an aid in the risk assessment of patients with chronic liver disease for development of HCC.
The serum biomarkers lectin-reactive alpha-fetoprotein (AFP-L3) and des-gamma-carboxy prothrombin (DCP) have been shown to be specific to hepatocellular carcinoma (HCC) and their combined use aids in clinical assessment for early detection. Adding the two biomarkers, AFP-L3 and DCP, to your current HCC surveillance practice can increase your chances of detecting early HCC. These tests are available now in the United States and Canada.
We have 3 prizes for you!
• 2 Maui Jim Gift Certificates
• $500 Gift Certificate for the Allison Inn & Spa
Enter to win by clicking the entry button below and submitting your name and email address. You can enter 1 time at each vendor to improve your odds of winning. *Invalid email address entries and duplicate entries from the same showcase site will be deleted before the drawing.